Capstone Therapeutics (CAPS) Stock Price, News & Analysis

Company Overview

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Key Stats

• Today's Range: $1.13 to $1.26
• 50-Day Range: $1.01 to $1.71
• 52-Week Range: $0.96 to $16.18
• Volume: 1.26 million shs
• Average Volume: 1.89 million shs
• Market Capitalization: $8.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CAPS Stock Analysis - Frequently Asked Questions

How have CAPS shares performed this year?

Capstone Therapeutics' stock was trading at $2.40 at the beginning of 2025. Since then, CAPS stock has decreased by 50.8% and is now trading at $1.18.

How were Capstone Therapeutics' earnings last quarter?

Capstone Therapeutics Corp. (NASDAQ:CAPS) announced its earnings results on Friday, August, 15th. The company reported ($0.13) earnings per share for the quarter. The business had revenue of $12.85 million for the quarter.

When did Capstone Therapeutics IPO?

Capstone Therapeutics (CAPS) raised $5 million in an initial public offering on Thursday, March 6th 2025. The company issued 1,250,000 shares at $4.00 per share.

When did the company's lock-up period expire?

Capstone Therapeutics's lock-up period expired on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its initial public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Capstone Therapeutics' major shareholders?

Capstone Therapeutics' top institutional shareholders include World Investment Advisors (0.40%).

How do I buy shares of Capstone Therapeutics?

Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/15/2025
• Today: 10/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CAPS
• CIK: 887151
• Web: N/A
• Phone: (708) 371-0660
• Fax: 602-286-5300
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 0.97
• Quick Ratio: 0.41

Sales & Book Value

• Annual Sales: $43.38 million
• Price / Sales: 0.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($19.40) per share
• Price / Book: -0.06

Miscellaneous

• Outstanding Shares: 7,291,000
• Free Float: 2,979,000
• Market Cap: $8.60 million
• Optionable: N/A
• Beta: -0.81